Cellytics® NK is expected to be the first product to utilize single-cell analysis for cancer screening diagnostics.
It has the potential to create a new wave in the field of early cancer diagnosis.

Recently, we started to use Cellytics® NK for monitoring the therapeutic effect of NK cell therapeutics in lung cancer patients.
I believe this new and amazing technology will bring about innovative achievements in the field of immune cell therapy development.

The diagnostic value of the number and activity of NK cells in blood cancer patients has been overlooked.
I am confident that Cellytics® NK will be a useful tool in verifying this diagnostic value.

I am conducting research using Cellytics® NK to examine the number and
activity of NK cells in patients with alcoholic liver disease, both for diagnosis and to monitor treatment progress.
I expect this to aid in a deeper study of the effects of alcohol on immune function.